The marketing study follows the successful two-stage dental implant trial and market authorisation of CelGro in the European Union for dental bone and soft tissue applications.
Study results further validate CelGro as a superior medical device for bone and soft tissue repair and will assist in driving market adoption.
“CelGro as the best in class collagen membrane”
Orthocell’s managing director Paul Anderson said: “CelGro’s ability to deliver superior bone growth has the potential to revolutionise dental implant techniques and is highly desired by physicians and potential partners.
“The latest results provide further evidence that positions CelGro as the best in class collagen membrane.”
The 10 patients treated in the marketing study had previously suffered, in some cases for many years, from damaged, missing or diseased teeth.
Symptoms prior to treatment included severe irritation, bleeding gums, an inability to chew or eat certain foods and enjoy a normal diet.
Treatment completion in four months
After surgery with CelGro the impact on patients’ lives was ‘significant’ with patients having successfully generated enough new bone to stabilise their implants and complete treatment in about four months.
This is almost half the time of the usual two-stage dental implant treatment.
The performance study underpins the compatibility and versality of CelGro as a platform technology and highlights the potential to extend the company’s innovative dental product range.
Orthocell is also leveraging the EU regulatory approval and finalising its submission for US regulatory clearance.